Tecan Group AG : Tecan's OEM partner Dako unveils new platform at global congress

   Tecan Group AG : Tecan's OEM partner Dako unveils new platform at global

Tecan Group AG / Tecan's OEM partner Dako unveils new platform at global
congress . Processed and transmitted by Thomson Reuters ONE. The issuer is
solely responsible for the content of this announcement.

Männedorf, Switzerland, March 7, 2013 - The Tecan Group (SIX Swiss Exchange:
TECN) announced today that its OEM partner Dako, an Agilent Technologies
Company and worldwide provider of cancer diagnostics, unveiled the new
advanced staining platform at the 2013 USCAP congress in Baltimore, Maryland,
USA. Earlier this week, it was presented to a global gathering of pathologists
and lab personnel for the first time.

In May 2011, Tecan signed a major OEM agreement with Dako for the development
and supply of an advanced staining platform. Formerly the development program
was referred to by Tecan as P16. The solution, Dako Omnis, comprises hardware,
software and reagents.

Lars Holmkvist, CEO of Dako said: "The Dako Omnis offers full-automation to
satisfy the needs of large-scale laboratories, hospitals and universities.
Tecan has been our ideal development partner for this system due to their
strong application know-how and experience with end-customer workflows in the
IHC and ISH segment. Furthermore, as we progressed through the development, we
found that Tecan shared our values of innovation and ownership and that their
experience in system integration was key in bringing the Dako OMNIS to

Tecan CEO David Martyr commented: "We are delighted to work with Dako, a
global leader in the fast growing area of tissue-based cancer diagnostics. The
Dako Omnis is really setting a new standard for advanced staining. We expect
sales volumes for Tecan from the supply of the Dako Omnis to accelerate from
the second half of this year with a substantial contribution to our sales
growth from 2014 onwards. Based on our partnership today, we look forward to
further intensify our relationship with Dako in the future."

Methods used in the diagnosis of abnormal cells such as those found in
cancerous tumors include immunohistochemistry (IHC) and in situ hybridization
(ISH). The Dako Omnis automates both IHC and ISH processes, meaning entire
patient cases can be processed simultaneously. This allows pathologists to
make quicker, more informed diagnoses. Oncologists can in turn prescribe
relevant therapy with less anxiety-ridden waiting time for patients.

With continuous loading, batch loading and overnight run options all
available, Dako Omnis sets new standards for what customers can expect from an
automated platform in terms of flexibility, capacity, efficiency and
traceability of slides. The platform provides state-of-the-art software to
bring lab control to a new level. Now, key processes such as slide processing
and instrument maintenance can be traced to individual operators, greatly
increasing quality control.

About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments
and solutions in biopharmaceuticals, forensics and clinical diagnostics. The
company specializes in the development, production and distribution of
automated workflow solutions for laboratories in the life sciences sector. Its
clients include pharmaceutical and biotechnology companies, university
research departments, forensic and diagnostic laboratories. As an original
equipment manufacturer (OEM), Tecan is also a leader in developing and
manufacturing OEM instruments and components that are then distributed by
partner companies. Founded in Switzerland in 1980, the company has
manufacturing, research and development sites in both Europe and North America
and maintains a sales and service network in 52 countries. In 2012, Tecan
generated sales of CHF391million (USD416million; EUR323million).
Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN;
ISIN CH0012100191).

For further information:
Tecan Group
Martin Braendle
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89

Press Release (PDF)


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Tecan Group AG via Thomson Reuters ONE

--- End of Message ---

Tecan Group AG
Seestrasse 103 Männedorf Switzerland

ISIN: CH0012100191;
Press spacebar to pause and continue. Press esc to stop.